CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

News and Events

Latest News

Does the Evidence Support the Hype Around Antiviral Treatments for COVID-19?

May 27, 2020
Media Advisory Huge response to upcoming CADTH webinar on remdesivir and hydroxychloroquine shows demand among health care decision-makers for evidence on the effectiveness of these therapies. Ottawa, Ontario — More than 1,500 people have registered for a CADTH webinar that will provide an overview of the available science behind remdesivir an...

CADTH Board of Directors Names Suzanne McGurn as Next President and CEO

May 19, 2020
OTTAWA – The CADTH Board of Directors announced today that Suzanne McGurn has been appointed as the next President and Chief Executive Officer of CADTH, effective July 6, 2020. Ms. McGurn will succeed Dr. Brian O’Rourke, who announced his retirement from CADTH in October 2019 after serving as President and Chief Executive Officer since 2010. D...

Patient Input and Clinical Experts: etonogestrel

May 6, 2020
CADTH has received the following notice(s) of pending drug submission(s). Brand name TBC Generic name etonogestrel Manufacturer Merck Canada Inc. Indication(s) Prevention of pregnancy Project Number SR0648-000 Call for patient input 2020-05-06 Patient input deadlin...

Upcoming Events

Does the Evidence Support the Hype? COVID-19 and Antiviral Treatments

May 29, 2020
The magnitude of the COVID-19 pandemic globally is generating considerable interest in options to prevent infection and minimize the impact if infection occurs. Pre-exposure prophylaxis and post-exposure treatment with a group of drugs called antivirals, sometimes in combination with an antibiotic, have been the subject of public debate and, at ...